; and (D) for each of the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Office of Regulatory Affairs, and the Office of the Commissioner, the actual number of employees described in subparagraph (C) (both full-time equivalents and employees dedicated to such activities on a part-time basis) for whom time reporting is required as described in subparagraph (C), and the number of such employees required to estimate time dedicated to the review of biosimilar biological product applications. . 3. FDA analysis of use of funds (a) PDUFA reports (1) Analysis in PDUFA performance reports Section 736B(a) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379h–2(a) ), as amended by section 2(a), is further amended by adding at the end the following: (5) Analysis For each fiscal year, the Secretary shall include in the report an analysis of the following: (A) The difference between the number of human drug applications filed and the number of approvals or complete response letters issued by the agency, accounting for— (i) such applications filed during one fiscal year for which a decision is not scheduled to be made until the following fiscal year; (ii) such applications pending with the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research that did not meet the goals for the corresponding fiscal year and the future plans of the Food and Drug Administration to meet these goals